BLU554 was derived from BLU9931 with improved pharmaceutical properties, which is now in Phase I clinical trial to treat HCC with elevated FGF19–FGFR4 axis (NCT02508467) (Table 1) [63]. The gene discussed is FGFR4; the disease is hepatocellular carcinoma.